IX. Chronic lymphocytic leukemia for the clinician
Explore this paper's citation graph
Summary
This review integrates knowledge and proposes a treatment algorithm for patients with CLL and shows that chemoimmunotherapies composed of fludarabine and rituximab (with or without cyclophosphamide) may improve overall survival when used as therapy for CLL patients.
- Type
- article
- Published
- 2011-06-01
- Cited by
- 1
- References
- 15
- Access
- Open access
- OpenAlex
- https://openalex.org/W2131897387
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:56227808
Keywords
Alemtuzumab, Fludarabine, Medicine, Ofatumumab, Chronic lymphocytic leukemia
References
- Prognostic factors in chronic lymphocytic leukemia—what do we need to know?
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
- Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.
- Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
- State of the art treatment of chronic lymphocytic leukaemia.
- State-of-the-art treatment of chronic lymphocytic leukemia.
- Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
- Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
- Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia.
- Comorbidity and functional status are independent in older cancer patients.
- Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab (FC-Cam) in Patients with Relapsed or Genetic High-Risk CLL: Final Analysis of the CLL2L Trial of the German CLL Study Group.
- Overall Survival Advantage and Acceptable Safety Profile with Fludarabine In Combination with Alemtuzumab (FluCam) In Previously Treated Patients with Advanced Stage Chronic Lymphocytic Leukemia
Cited by
Related papers
- Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia
- Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015
- Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
- Initial treatment of CLL: integrating biology and functional status.
- ECONOMIC EVALUATION OF BENDAMUSTINE PLUS RITUXIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- Chronic Lymphocytic Leukemia: Chemoimmunotherapy is over? No
- Resource use and Health-Care Costs of Chronic Lymphocytic Leukemia in Slovakia
- Advances in first‐line treatment of chronic lymphocytic leukemia: current recommendations on management and first‐line treatment by the German CLL Study Group (GCLLSG)